Company Encyclopedia
View More
name
AUSTAR
06118.HK
Austar Lifesciences Limited, an investment holding company, engages in the provision of integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. The company operates through Integrated Process and Packaging Equipment & Systems (IPS); Consulting, Digitalization and Construction (CDC); and Life Science Equipment and Consumables (SIC) segments. It also offers clean utility and bioprocess equipment, clean room, automation control and monitor system; bioprocess equipment consumables, and laboratory solutions. In addition, the company provides pharmaceutical process contamination control; packaging and aseptic containment; biosafety and lab animal equipment and consumables, as well as offers powder and solid equipment; freeze-dryer, sterile filling and visual inspection equipment.
697.22 B
06118.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Life Sciences Tools and ServicesIndustry
Industry Ranking13/14
Industry medianC
Industry averageB
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE4.43%C
    • Profit Margin2.41%C
    • Gross Margin21.02%D
  • Growth ScoreC
    • Revenue YoY-5.28%D
    • Net Profit YoY152.11%A
    • Total Assets YoY-3.31%D
    • Net Assets YoY5.74%B
  • Cash ScoreC
    • Cash Flow Margin4151.55%A
    • OCF YoY-5.28%D
  • Operating ScoreB
    • Turnover0.7B
  • Debt ScoreD
    • Gearing Ratio60.05%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Austar Lifesciences Limited's (HKG:6118) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

    Austar Lifesciences Limited (HKG:6118) shares surged 27% in the past month and 79% over the last year. Despite this, the company's price-to-sales (P/S) ratio of 0.5x suggests potential concerns, as revenue has declined by 5.4% last year and 35% over three years. The industry anticipates 17% growth in the next year, contrasting with Austar's downward trend. Investors may be cautious, as the low P/S reflects expectations of continued poor performance. Additionally, there are four warning signs regarding the company's future prospects.

    Simplywall·
    HK
    06118
    +1.03%
    Simplywall·
    HK
    06118
    +1.03%

    Understanding the Market | AUSTAR surged over 54% in the late trading session, AUSTAR Group is a provider of technology-based pharmaceutical engineering solutions

    AUSTAR Life Science Technology's late trading gains expanded by over 54%. As of the time of writing, it rose by 48.04%, priced at HKD 1.51, with a transaction volume of HKD 8.4778 million. Public information shows that Hong Kong AUSTAR Group is a technology-based pharmaceutical engineering solution provider. As one of the main members of the group, AUSTAR Life Science's products and services division covers nine sectors: sterile drug production contamination control consumables, equipment and services, environmental monitoring and testing systems, validation and single equipment, biological upstream process systems, disposable process systems, laboratory information technology, and life science consulting. AUSTAR Life Science Technology's interim results show that the profit attributable to shareholders was HKD 24.999 million, an increase of 325.37% year-on-year

    Zhitong·
    HK
    06118
    +1.03%
    Zhitong·
    HK
    06118
    +1.03%

    AUSTAR Life Science Technology released its interim results, with a profit attributable to shareholders of HKD 24.999 million, an increase of 325.37% year-on-year

    According to the Zhitong Finance APP, AUSTAR released its interim results for the six months ended June 30, 2025, with revenue of 662 million yuan (RMB, the same below), a year-on-year decrease of 5.57%; profit attributable to shareholders was 24.99 million yuan, a year-on-year increase of 325.37%; basic earnings per share were 0.05 yuan

    Zhitong·
    HK
    06118
    +1.03%
    Zhitong·
    HK
    06118
    +1.03%

    AUSTAR: Bian Ce appointed as Executive Director and member of the Risk Management Committee

    According to the announcement from AUSTAR, Mr. Chen Yuewu has resigned from his position as executive director due to other work arrangements and will no longer serve as a member of the board's risk management committee, effective from August 26, 2025. Mr. Bian Ce has been appointed as executive director and a member of the risk management committee to replace Mr. Chen, effective from the same date

    Zhitong·
    HK
    06118
    +1.03%
    Zhitong·
    HK
    06118
    +1.03%

    Austar Lifesciences Expects Profit Of RMB23-25 Million For HY

    Austar Lifesciences Ltd :EXPECTED PROFIT OF RMB23-25 MILLION FOR HYSEES PROFIT GROWTH DUE TO EXCHANGE GAINS, OTHERS IN HY

    Reuters·
    HK
    06118
    +1.03%
    Reuters·
    HK
    06118
    +1.03%
    © 2025 Longbridge｜Disclaimer